Myriad Genetics announces senior leadership change: Raha named CEO
Myriad Genetics Inc., a Salt Lake City-based provider of molecular diagnostics testing, has named Sam Raha, the company’s current chief operating officer, as president and CEO of the company and as a member of the board. The change will be effective April 30. Raha replaces Paul J. Diaz, who is stepping down to join private equity firm Cressey & Co. Diaz will continue to serve as a consultant to Raha and the board for another year.
“Since joining Myriad in December 2023, Sam has played an integral role in shaping the company’s long-term growth strategy, while delivering new perspectives and expertise to advance our business initiatives, operational excellence and profitability,” said S. Louise Phanstiel, chair of Myriad’s board of directors. “Having engaged in a robust succession planning process, the board is very pleased and excited to welcome Sam as Myriad’s next president and chief executive officer. His deep background in the diagnostics industry and leadership throughout his career are crucial to the continued growth of Myriad and the achievement of our mission to advance health and well-being for all, while creating long-term value for our shareholders.”
“I am honored to take on the leadership of Myriad at this pivotal point in the company’s evolution and I am grateful for Paul’s leadership in both transforming the company and delivering a foundation of profitable growth,” said Raha. “I am now looking forward to leading the team and accelerating our strategy to drive continued growth and profitability through our comprehensive portfolio and future innovation, while continuing to leverage the company’s multi-year investment program and focusing on the needs of patients and the health care providers who serve them.”
“It has been an honor to serve as Myriad’s president and CEO and further the company’s vision of providing genetic insights that help people take control of their health and enable health care providers to better detect, treat and prevent disease,” said Diaz. “I believe the company is well-positioned for the future and will continue to grow and innovate under Sam’s leadership.”
Myriad also announced that Mark S. Verratti, the compnay’s current chief commercial officer, will be promoted to chief operating officer upon Raha’s appointment.